Ipsen receives its second Shingo Prize for operational excellence
October 14 2024 - 11:00AM
- Ipsen is
the first pharma company in the world to receive Shingo Prizes for
two sites producing treatments for patients
- Ipsen’s
first Shingo Prize was received by its production site in Signes,
France in 2020, followed by the site in Dublin, Ireland
today
- The Shingo
Prize represents the highest standard of operational excellence in
the world
PARIS, FRANCE, 14 October 2024
- Ipsen (Euronext: IPN; ADR: IPSEY) announced today that
its Dublin, Ireland production site has received the Shingo Prize
for operational excellence. This is Ipsen’s second Shingo Prize,
with its site in Signes, France, receiving the first award in
2020.
Created in 1988, the Shingo Prize recognizes
companies across all sectors that demonstrate a strong culture of
operational excellence, deeply rooted in the mindset and behaviors
of all staff, management and employees alike. This prestigious
award is given to a maximum of five companies each year.
Ipsen’s Dublin, Ireland site has almost 200
employees and produces the active pharmaceutical ingredients for
two of Ipsen’s medicines.
“It’s truly an honor to receive this second
Shingo Prize,” said Aidan Murphy, Executive Vice-President, Head of
Technical Operations, Ipsen. “Following the first prize our Signes
site received in 2020, we immediately saw the impact of the Shingo
mindset: every colleague understands how their work supports the
strategy and focuses on continuous improvement and alignment
between our values and behaviors. Bringing this level of excellence
to our industrial and manufacturing footprint has allowed us to
consistently deliver on our medicines and avoid shortages.”
“I’m extremely proud of the people at Ipsen and
their hard work that has created a fantastic culture at the Dublin
site,” said Paul Maginn, head of Excellence Enterprise and
Manufacturing Science & Technology who played a pivotal role on
the Shingo journey. “The Shingo Prize reflects the energy,
dedication and commitment of each person to embedding the Shingo
Model ™ across the organization.” Bénédicte Verley Hudry, Head of
the Dublin site, said, “I had a remarkable experience during the
Shingo assessment in Dublin. The Shingo Model emphasizes the
importance of authentic engagement and dedication from all team
members, and Dublin team truly embodies these principles.”
ENDS
About Ipsen
We are a global biopharmaceutical company with a
focus on bringing transformative medicines to patients in three
therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
Ipsen contacts
Media
- Sam
Howland | +44 (0) 7514 49 25 68 |
sam.howland@ipsen.com
- Jennifer
Smith-Parker | + 44 7843 137764 |
jennifer.smith-parker.ext@ipsen.com
Disclaimers and/or Forward-Looking
StatementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Ipsen PR _ Shingo Gold Prize_14102024
Ipsen (EU:IPN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Ipsen (EU:IPN)
Historical Stock Chart
From Feb 2024 to Feb 2025
